Eli Lilly And Co vs Synopsys, Inc. — how do they compare? Eli Lilly And Co trades at $1,205.55 (market cap $1.08T), while Synopsys, Inc. trades at $412.44 (market cap $78.68B). The key difference: Eli Lilly And Co is far larger — about 13.7× Synopsys, Inc.'s market cap, and Eli Lilly And Co pays a 0.57% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| LLY | SNPS | |
|---|---|---|
Market Cap | $1.08T | $78.68B |
Sector | Health | Technology |
52-Week High | $1.24K | $625.80 |
52-Week Low | $639.43 | $372.33 |
Enterprise Value | $1.13T | $87.04B |
Dividend Yield | 0.57% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Synopsys (SNPS) trades at $411.68, down 1.04% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish overall signal despite recent volatility, with strong analyst support (82.76% buy ratings) and a consensus price target of $551.00. Recent earnings beats and strategic moves like the Ansys acquisition highlight robust growth prospects in the semiconductor design software space, though high valuation multiples and significant cash flow volatility warrant caution.
The outlook for SNPS remains positive driven by AI-driven demand and recurring revenue streams, but investors face risks from elevated valuations, integration challenges from acquisitions, and semiconductor cycle sensitivity. The stock's current price near key support levels offers a potential entry point for long-term growth investors, contingent on sustained execution and market conditions.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →